A Study of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin) in Participants With Solid Tumors
Clinical trial NCT03386942 · COMPLETED
Trial details
- NCT number
- NCT03386942
- Sponsor
- Eisai Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2017-11-28
- Primary completion
- 2022-10-26
- Enrollment
- 82
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.